Definium Therapeutics grants CCO 125K shares

Definium Therapeutics granted its chief commercial officer 125,000 performance-based common shares that vest over time and upon specified milestones.

Rhea-AI Filing Summary

Definium Therapeutics, Inc. (symbol: DFTX) is the issuer of record for a Form 4 filing submitted to the SEC. Wiley Matthew T. reported acquisition or exercise transactions in this Form 4 filing.

Definium Therapeutics, Inc. (DFTX) reported that Chief Commercial Officer Matthew T. Wiley received a grant of 125,000 common shares on September 14, 2026, as the third tranche of performance share units originally granted effective March 17, 2025. These shares remain subject to vesting based on Wiley’s continued employment through March 17, 2028 and the achievement of specified clinical and regulatory milestones. Following this award, Wiley directly holds 362,133 common shares. No Rule 10b5-1 trading plan is reported in connection with this grant.

Insider Trade Summary

Grant/Award: 125,000 shares

Grant/Award 1 txn

Insider Wiley Matthew T.

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	125,000	$0.00	$0.00

Holdings After Transaction: Common Shares — 362,133 shares (Direct)

Footnotes (1)

1. F1. The common shares represent the third tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.

Key Figures

Shares granted: 125,000 shares Shares held after transaction: 362,133 shares Grant price per share: $0.00 per share +1 more

4 metrics

Shares granted 125,000 shares Common shares granted to Matthew T. Wiley on September 14, 2026 as a performance share unit tranche

Shares held after transaction 362,133 shares Direct common share holdings of Matthew T. Wiley following the grant

Grant price per share $0.00 per share Reported price for the 125,000-share performance-based grant

Vesting end date March 17, 2028 Continued employment required through this date for vesting of the performance share units

Key Terms

performance share units, clinical and regulatory milestones, contingent right

3 terms

performance share units financial

"The common shares represent the third tranche of performance share units granted effective March 17, 2025"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

clinical and regulatory milestones medical

"subject to, the achievement of certain clinical and regulatory milestones set forth"

Clinical and regulatory milestones are the key steps a medical product must clear as it is tested on patients and reviewed by government health authorities, such as completing major clinical trials, filing safety and effectiveness data, or receiving marketing approval. Investors watch these checkpoints like milestones on a roadmap because each one sharply changes the odds that a product will reach patients and generate revenue, much like a car passing inspection before it can be sold.

contingent right financial

"Each performance share unit represented a contingent right to receive one common share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DFTX disclose for Matthew T. Wiley?

Definium Therapeutics disclosed that Chief Commercial Officer Matthew T. Wiley received a grant of 125,000 common shares on September 14, 2026 as a performance share unit tranche, subject to employment-based vesting and clinical and regulatory milestones.

How many Definium Therapeutics (DFTX) shares does Matthew T. Wiley hold after this Form 4?

After the September 14, 2026 award, Matthew T. Wiley directly holds 362,133 common shares of Definium Therapeutics, as reported in the Form 4 filing.

What are the vesting conditions on the 125,000 DFTX performance share units?

The 125,000 common shares represent performance share units that remain subject to continued employment through March 17, 2028 and to the achievement of specified clinical and regulatory milestones under the Performance Share Unit Award Agreement.

When were the underlying performance share units for DFTX originally granted?

The performance share units underlying this third tranche of 125,000 common shares were originally granted effective March 17, 2025, according to the Form 4 footnote.

Was the DFTX insider grant to Matthew T. Wiley under a Rule 10b5-1 plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not selected, so this reported grant is not affirmed as made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 08:30 AM Accepted by SEC EDGAR 09/14/2026 - 08:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wiley Matthew T.

(Last) (First) (Middle)

C/O DEFINIUM THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, SUITE 8500

(Street)

NEW YORK NEW YORK 10007

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/14/2026		A		125,000(1)	A	$0.00	362,133	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The common shares represent the third tranche of performance share units granted effective March 17, 2025, and remain subject to vesting based on the Reporting Person's continued employment through March 17, 2028. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.

	/s/Mark Sullivan, Attorney-in-Fact for Matthew T. Wiley	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)